Finance

Beta
Lists
DNLI:NASDAQ
Denali Therapeutics Inc
$24.82
+0.20%
(+0.050) 1D
$24.82
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNLI...
Open
$25.14
High
$25.69
Low
$24.72
Mkt. cap
3.94B
Avg. vol.
1.88M
Volume
1.49M
52-wk high
$25.69
52-wk low
$12.58
EPS
-$2.88
Beta
1.03
Shares outstanding
158.71M
No. of employees
507
Open
$25.14
High
$25.69
Low
$24.72
Mkt. cap
3.94B
Avg. vol.
1.88M
Volume
1.49M
52-wk high
$25.69
52-wk low
$12.58
EPS
-$2.88
Beta
1.03
Shares outstanding
158.71M
No. of employees
507
News stories
From sources across the web
About Denali Therapeutics Inc
CEO-
Employees507
Founded2013
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitedenalitherapeutics.com
Analyst Ratings
Based on 13 analysts giving stock ratings to DNLI in the past 3 months
Strong Buy
Buy
13
Hold
0
Sell
0
12 month forecast
Based on 13 Wall Street analysts offering 12 month price targets for DNLI in the last 3 months.
Highest
Current $24.82
$42.00 (+69.22%)
Average
$35.00 (+41.02%)
Lowest
$23.00 (-7.33%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Michael Yee
UBS
Buy
Maintained
$25.00
+0.7%
06/16/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$35.00
+41%
05/26/2026
Myles Minter
William Blair
Buy
Maintained
-
-
05/22/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
05/22/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+61.2%
05/22/2026
David Hoang
Deutsche Bank
Buy
Maintained
$31.00
+24.9%
05/22/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$42.00
+69.2%
05/22/2026
Jay Olson
Oppenheimer
Buy
Maintained
$40.00
+61.2%
05/11/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+57.1%
05/11/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/08/2026
Laura Chico
Wedbush
Buy
Maintained
$23.00
-7.3%
05/08/2026
Charles Moore
Robert W. Baird
Buy
Maintained
$34.00
+37%
04/07/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$41.00
+65.2%
03/29/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
$30.00
+20.9%
03/13/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
02/23/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.69 / -$0.71
+2.17%beat
Revenue / Est. (USD)
- / 2.32M
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
102.70M
101.95M
97.90M
103.85M
Cost of revenue
102.70M
101.95M
97.90M
103.85M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.27M
35.48M
39.46M
33.51M
Operating expense
32.27M
35.48M
39.46M
33.51M
Total operating expenses
134.96M
137.43M
137.36M
137.36M
Operating income
-134.96M
-137.43M
-137.36M
-137.36M
Other non operating income
-
-
-
-
EBT including unusual items
-124.12M
-126.90M
-128.45M
-128.45M
EBT excluding unusual items
-124.12M
-126.90M
-130.09M
-129.71M
Income tax expense
-
-
102.00K
-
Effective tax rate
-
-
-0.08%
-
Other operating expenses
-
-
-
-
Net income
-124.12M
-126.90M
-128.55M
-128.45M
Net profit margin
-
-
-
-
Earnings per share
-0.72
-0.74
-0.73
-0.69
Interest and investment income
11.04M
10.73M
7.28M
7.83M
Interest expense
-200.00K
-200.00K
-
-179.00K
Net interest expenses
10.84M
10.53M
7.28M
7.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-131.01M
-133.57M
-133.58M
-133.60M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer